IP Library › Granted Patent US 10,961,493
Granted Patent B2
US 10,961,493 · App. 15/743,913 · Granted Mar 30, 2021

Container for cell administration, storage or culturing

Inventors: Tatsuya Higuchi (Osaka, JP); Kozue Komazawa (Osaka, JP); Yoshiko Mohara (Osaka, JP); Takayuki Dempo (Tokushima, JP); Masuhiro Nishimura (Tokushima, JP)
Assignees: DAIKIN INDUSTRIES, LTD.; OTSUKA PHARMACEUTICAL FACTORY, INC.
C12M23/20A61K35/28C09D127/18C09D127/20C09D129/10C12M23/14C12N5/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,493
App. No.
15/743,913
Granted
Mar 30, 2021
Kind
B2
Abstract

When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF 3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF 2 H group terminals in the fluororesin of 70 or less per 1×10 6 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).

Claims (17)

1. A container for administering, storing or culturing a mammal cell, wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having a total number of a non-fluorinated group terminal and a —CF 2 H group terminal in the fluororesin of 70 or less per 1×10 6 carbon atoms, wherein the fluororesin is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer.

2. The container for administering, storing or culturing a mammal cell according to claim 1 , wherein the container is a bag.

3. The container for administering, storing or culturing a mammal cell according to claim 1 , wherein the mammal cell is an adhesive cell.

4. The container for administering, storing or culturing a mammal cell according to claim 1 , wherein the mammal cell is a mesenchymal stem cell.

5. A container for administering, storing or culturing a mammal cell, wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having one or more —CF 3 terminal groups, wherein the fluororesin is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer, wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having a number of the non-fluorinated group terminals of 70 or less per 1×10 6 carbon atoms.

6. The container for administering, storing or culturing a mammal cell according to claim 5 , wherein the container is a bag.

7. A method for administering, storing, or culturing a mammal cell comprising:

a step of administering the mammal cell using a container wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having a total number of a non-fluorinated group terminal and a —CF 2 H group terminal in the fluororesin of 70 or less per 1×10 6 carbon atoms, wherein the fluororesin is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer; or

a step of storing or culturing the mammal cell within the container.

8. The method for administering, storing, or culturing a mammal cell according to claim 7 , wherein the container is a bag.

9. The method for administering, storing, or culturing a mammal cell according to claim 7 , wherein the mammal cell is an adhesive cell.

10. The method for administering, storing, or culturing a mammal cell according to claim 9 , wherein the mammal cell is a mesenchymal stem cell.

11. A method for administering, storing, or culturing a mammal cell comprising:

a step of administering the mammal cell using a container wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having one or more —CF 3 terminal groups, wherein the fluororesin is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer; or

a step of storing or culturing the mammal cell within the container,

wherein a surface of the container in contact with the mammal cell is formed of a fluororesin having a number of the non-fluorinated group terminals of 70 or less per 1×10 6 carbon atoms.

12. The method for administering, storing, or culturing a mammal cell according to claim 11 , wherein the container is a bag.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2018
From: HIGUCHI, TATSUYA; KOMAZAWA, KOZUE; MOHARA, YOSHIKO; DEMPO, TAKAYUKI; NISHIMURA, MASUHIRO
To: DAIKIN INDUSTRIES, LTD.; OTSUKA PHARMACEUTICAL FACTORY, INC.
Reel/Frame 045134/0959 →
Priority Claims (2)
JP JP2015-142201 · Jul 16, 2015 · national
JP JP2016-004339 · Jan 13, 2016 · national
Continuity (1)
Related Publication 20180201890A1 · Jul 19, 2018